(NewsDirect)
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Lathamtells Proactive the company has begun a Phase 2 clinical trial,testing the safety and efficacy of its IHL-657A drug candidate inpatients with rheumatoid arthritis. Research firm Avance Clinical willmanage the trial across up to 10 sites in Australia and New Zealand,overseeing responses from 120 participants as they evaluate howIHL-657A treats patient pain and function over 24 weeks.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.